CClinicalTrials.gg
Status unknownNCT03816566Updated Jan 25, 2019

Validation of a Wearable Non-invasive Device (the Patch)

An interventional study of patch in Sleep Apnea, sponsored by BresoTEC Inc.. Status unknown at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-25.

Sponsored by BresoTEC Inc. · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

BresoTEC has designed and developed a standalone wearable device (the patch), that can record tracheal sounds with a microphone attached just above the suprasternal notch of the subject.

Read the detailed description

The patch also has a 3-dimensional accelerometer to record body position. Furthermore, the patch records oxygen saturation using an FDA cleared pulse oximeter, Nonin 3150 WristOx2® with Bluetooth Low Energy. We have developed advanced signal processing algorithms to detect apneas and hypopneas. Many of these techniques for analyzing breathing sounds and detecting apneas and hypopneas have been published in peer-reviewed journals.

The goal of this study is to validate the patch against polysomnography (PSG) for use as an aid in the diagnosis of sleep apnea for adult patients. Our primary objective is to assess whether the estimated apnea-hypopnea index (AHI) calculated by the patch agrees with the results of an in-laboratory PSG.

02

Conditions studied

  • Sleep Apnea
03

In context

Sleep Apnea Syndromes

2,162 studies on the registry are indexed under Sleep Apnea Syndromes; 290 are open to participants now.

This study's planned enrollment of 60 is above the median of 53 across 1,386 interventional studies indexed under Sleep Apnea Syndromes.

Browse Sleep Apnea Syndromes studies →

Lead sponsor

This is the only study on the registry with BresoTEC Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Inclusion criteria are men and women 18 years and above, who are referred to either the University Health Network (UHN), Toronto Rehabilitation Institute (TRI) or Toronto General Hospital sleep laboratories for overnight PSG because of a suspicion of a sleep disorder. It is intended for the general outpatient population.

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria are patients with suspected complicated co-morbidities including in-hospital patients and those who self-report diagnosis of heart failure, recent stroke, neuromuscular disorders, renal failure, obesity hypoventilation, COPD, or other severe lung diseases.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Wearable Device and PSG

    The device under investigation (the patch) will be used in patients undergoing overnight polysomnography simultaneously, to compare the accuracy of the investigational device against the gold standard for the diagnosis of sleep apnea.

    Device: patch

Interventions

  • Devicepatch

    A standalone wearable device (the patch), that can record tracheal sounds with a microphone attached just above the suprasternal notch of the subject. The patch also has a 3-dimensional accelerometer to record body position. Furthermore, the patch records oxygen saturation using an FDA cleared pulse oximeter, Nonin 3150 WristOx2® with Bluetooth Low Energy.

06

What researchers measure

Primary outcomes

  1. Estimation of AHI

    Validate the performance of the patch in estimating the AHI compared to an in-laboratory PSG.

    Time frame: 8 months

Secondary outcomes

  1. Estimation of body position

    Validate the performance of the patch in estimating body position during sleep compared to an in-laboratory PSG.

    Time frame: 8 months

07

Study locations

1 of 2 sites recruiting
  • Toronto Rehabilitation Institute
    Toronto, Ontario M5G 2A2, Canada
    • Clodagh Ryan, MD · Contact · Clodagh.Ryan@uhn.ca · 416 340 4719
    • Clodagh Ryan, MD · Principal investigator
    Recruiting
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
    • Clodagh Ryan, MD · Contact
    • Clodagh Ryan, MD · Principal investigator
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03816566
Lead sponsor
BresoTEC Inc.
Responsible party
Sponsor
First posted
Jan 25, 2019
Start date
Dec 23, 2018
Primary completion
Aug 23, 2019 (estimated)
Completion
Aug 23, 2019 (estimated)
Last update
Jan 25, 2019

Study contacts

Hisham Alshaer, MD, PhD
Contact
Hisham.Alshaer@uhn.ca
416-597-3422 ext. 7959
Clodagh Ryan, MD
principal investigator · Toronto General Hospital & Toronto Rehabilitation Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion